Recent research from the US shows scientists have found that rare and aggressive neuroendocrine tumours shrink through a combination of two common immunotherapy drugs.
Research results were presented at the American Association for Cancer Research Annual Meeting 2019 and show a significant clinical benefit for patients with high-grade neuroendocrine carcinoma.
Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.
Shaping the future of cancer control together We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year
Recruiting NET health professionals for International Delphi survey Development of a neuroendocrine tumour (NET) nutrition-risk screening tool to identify patients requiring nutrition intervention and education
